| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
(2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxylic acid itself does not have a defined biological target. It is a synthetic intermediate. When incorporated into peptides, the 4-hydroxyproline residue can stabilize triple-helical structures in collagen-like peptides, interact with proline hydroxylases (e.g., PHD2), or modulate binding to proline-rich motifs in SH3 domains. The non-8-enoyl chain can be modified for conjugation to drugs or targeting ligands. The Boc-protected amino group (at the 2-position) provides a handle for further elongation. It is a proline derivative.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The compound itself has no direct in vitro biological activity. It is used as a building block for peptide synthesis, not as a test article. After incorporation into a peptide and removal of protecting groups, the resulting peptide may exhibit biological activities (e.g., collagen-mimetic binding to integrins). No IC50 or EC50 data for the building block are available. |
| ln Vivo |
No in vivo activity data are available for this building block. Peptides assembled using this intermediate may be evaluated in animal models (e.g., wound healing models for collagen-like peptides, or cancer models for peptide-drug conjugates). No data exist.
|
| Enzyme Assay |
The compound is not used directly in binding assays. Standard chemical analysis: HPLC with C18 column, UV detection at 210 nm, mobile phase water/acetonitrile (0.1% TFA). NMR in CDCl3 or DMSO-d₆ confirms structure (the terminal alkene appears as characteristic multiplets). For use in peptide synthesis (SPPS), Fmoc-SPPS protocols apply: The compound can be incorporated as an N-protected amino acid using standard coupling reagents (HATU, HOBt, DIEA). No biological assays.
|
| Cell Assay |
No cell-based protocols are established for this building block. For peptides synthesized from it, typical cell assays include: cell adhesion assays with collagen-like peptides (seeding cells on peptide-coated plates, measuring attachment by crystal violet staining), or viability assays for peptide-drug conjugates in cancer cells. No data for the building block.
|
| Animal Protocol |
No animal studies have been conducted with this building block. For downstream peptides, typical in vivo studies: mice with dermal wounds treated topically with collagen-like peptides (1-10 mg/wound) to assess healing rate. Or mice bearing tumor xenografts treated intravenously with peptide-drug conjugate (10-50 mg/kg weekly). No data exist.
|
| ADME/Pharmacokinetics |
No PK data are available for this compound. It is not a drug candidate. If administered, the Boc group would be cleaved in acidic stomach, and the amide bonds might be hydrolyzed. The terminal alkene is metabolically labile (epoxidation). No ADME studies (half-life, bioavailability) reported. Soluble in DMSO, methanol, and DMF. Storage: powder at -20degC, desiccated.
|
| Toxicity/Toxicokinetics |
Safety: May cause skin and eye irritation. Harmful if swallowed (estimated LD50 >2000 mg/kg). Not classified as carcinogen or mutagen. Use standard PPE: gloves, lab coat, safety goggles, fume hood. Avoid inhalation of dust. The terminal alkene is reactive; avoid exposure to strong oxidizing agents or radical initiators unless intended. Stable as a powder.
|
| References | |
| Additional Infomation |
This compound is not an approved drug and has no clinical trial history. It is a research chemical for peptide synthesis and medicinal chemistry. The combination of hydroxyproline and a long-chain unsaturated acyl group is reminiscent of lipopeptides (e.g., polymyxins, daptomycin) and may be used to develop novel antimicrobial lipopeptides or collagen-targeting probes. Hydroxyproline is a key component of collagen, and peptides containing this residue have applications in tissue engineering, wound healing, and fibrosis research. The terminal alkene group allows for late-stage functionalization via thiol-ene click chemistry, enabling conjugation to fluorescent dyes, PEG, or other biomolecules. This building block is commercially available for research use only.
|
| Molecular Formula |
C19H32N2O6
|
|---|---|
| Molecular Weight |
384.47
|
| Exact Mass |
384.226
|
| CAS # |
552335-47-4
|
| PubChem CID |
20765202
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.391
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
27
|
| Complexity |
543
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C)(C)OC(=O)N[C@@H](CCCCCC=C)C(=O)N1C[C@@H](C[C@H]1C(=O)O)O
|
| InChi Key |
OMMAVELVJUFTFD-ILXRZTDVSA-N
|
| InChi Code |
InChI=1S/C19H32N2O6/c1-5-6-7-8-9-10-14(20-18(26)27-19(2,3)4)16(23)21-12-13(22)11-15(21)17(24)25/h5,13-15,22H,1,6-12H2,2-4H3,(H,20,26)(H,24,25)/t13-,14+,15+/m1/s1
|
| Chemical Name |
(2S,4R)-4-hydroxy-1-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]non-8-enoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (260.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6010 mL | 13.0049 mL | 26.0098 mL | |
| 5 mM | 0.5202 mL | 2.6010 mL | 5.2020 mL | |
| 10 mM | 0.2601 mL | 1.3005 mL | 2.6010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
